SCM
KALV

Suvretta Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Suvretta Capital Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$96M Hold
4,768,712
– – 2.45% 16
2025
Q4 		$77M Hold
4,768,712
– – 1.58% 27
2025
Q3 		$58.1M Sell
4,768,712
-186,288
-4% -$2.57M 1.49% 24
2025
Q2 		$56M Buy
4,955,000
+41,988
+0.9% +$513K 1.69% 21
2025
Q1 		$56.7M Hold
4,913,012
– – 2.1% 14
2024
Q4 		$41.6M Buy
4,913,012
+701,007
+17% +$7.26M 1.42% 24
2024
Q3 		$48.8M Buy
4,212,005
+20,000
+0.5% +$252K 1.56% 24
2024
Q2 		$49.4M Hold
4,192,005
– – 1.81% 17
2024
Q1 		$49.7M Buy
4,192,005
+1,508,000
+56% +$20.1M 1.85% 17
2023
Q4 		$32.9M Buy
2,684,005
+263,154
+11% +$2.39M 1.49% 25
2023
Q3 		$23.3M Buy
2,420,851
+386,345
+19% +$3.95M 1.26% 26
2023
Q2 		$18.3M Buy
2,034,506
+51,327
+3% +$473K 0.98% 37
2023
Q1 		$15.6M Buy
1,983,179
+910,877
+85% +$6.8M 0.66% 44
2022
Q4 		$7.25M Sell
1,072,302
-634,798
-37% -$3.4M 0.3% 53
2022
Q3 		$24.8M Sell
1,707,100
-221,100
-11% -$3.09M 1.03% 40
2022
Q2 		$19M Buy
1,928,200
+181,900
+10% +$2.01M 0.72% 46
2022
Q1 		$25.7M Hold
1,746,300
– – 0.79% 41
2021
Q4 		$23.1M Buy
1,746,300
+203,016
+13% +$3.23M 0.45% 47
2021
Q3 		$26.9M Buy
1,543,284
+352,183
+30% +$7.14M 0.45% 45
2021
Q2 		$28.5M Buy
1,191,101
+231,209
+24% +$6.05M 0.43% 52
2021
Q1 		$24.7M Buy
959,892
+650,992
+211% +$17.1M 0.36% 54
2020
Q4 		$5.87M Hold
308,900
– – 0.08% 72
2020
Q3 		$3.89M Buy
308,900
+61,900
+25% +$774K 0.07% 68
2020
Q2 		$2.99M Buy
247,000
+132,800
+116% +$1.41M 0.06% 63
2020
Q1 		$874K Buy
+114,200
New +$1.54M 0.02% 53

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Suvretta Capital Management's KALV Position: Q1 2026 in Review

Suvretta Capital Management held its KalVista Pharmaceuticals (KALV) position steady in Q1 2026 at 4,768,712 shares worth $96M. The position accounts for 2.45% of the portfolio, ranked #16.

Suvretta Capital Management first reported a position in KALV in Q1 2020 and has held it in 25 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Suvretta Capital Management held 4,768,712 shares of KalVista Pharmaceuticals worth $96M as of Q1 2026.
  • Suvretta Capital Management left its KalVista Pharmaceuticals share count unchanged in Q1 2026.
  • KalVista Pharmaceuticals made up 2.45% of Suvretta Capital Management's portfolio in Q1 2026, its #16 holding.
  • Suvretta Capital Management first reported a position in KalVista Pharmaceuticals in Q1 2020 and has held it in 25 quarters since.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Suvretta Capital Management's 13F filing for Q1 2026, filed 15 May 2026.